National, Federal and State Policy Updates: November 2022   Federal Policy Updates CMS Announces BPCI-A Extension through 2025 On October 13, CMS stated that the

National, Federal and State Policy Updates: October 2022    Federal Policy Updates  Congress Passes Continuing Resolution with FDA Reauthorization  On September 30, Congress passed a

National, Federal and State Policy Updates: September 2022  Federal Policy Updates  CMS Releases 2021 MSSP Performance Data  On August 30, CMS released financial and quality

National, Federal and State Policy Updates: July 20, 2022  Spotlight on Pediatrics On August 1, CMS outlined a roadmap for a new state Medicaid option

National, Federal and State Policy Updates: July 20, 2022  Spotlight on Oncology  On June 27, CMS introduced the Enhancing Oncology Model, a voluntary 5-year model

National, Federal and State Policy Updates: June 22, 2022 National Policy Update Spotlight on LGBT Health  In June, the Medicaid and CHIP Payment and Access

Healthcare Policy Update: June 17, 2022 National Policy Update Spotlight on Maternal Health On May 31, the American Hospital Association hosted a dialogue on the

Healthcare Policy Update: June 1, 2022 National Policy Update Spotlight on Behavioral Health On March 23, Senators Patty Murray (D-WA) and Richard Burr (R-NC) held

Limited Uptake of Biosimilars Despite Potential Cost Savings: Patent Expiration and Value-Based Contracting to Drive Market Changes  Summary: Biosimilars are drugs that reference a biologic

SCALE Education Market Research Insights Written by David Blaszczak, Senior Advisor at SCALE Healthcare Over the past decade, value-based care (VBC) models have been developed